Bio News
U.S.-based Cellares has signed an agreement with Seoul National University Hospital to test automated cell therapy manufacturing.
Seoul National University Hospital will assess whether the production process for genetically modified hematopoietic stem cells for a candidate treatment for paroxysmal nocturnal hemoglobinuria (PNH) can be adapted to Cellares’ automated platform, Cell Shuttle.
Through the collaboration, Cellares plans to develop an automated manufacturing strategy to support future U.S. clinical development of the hospital’s candidate.
Biobook Team
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
